Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research: Personalized Infectious Disease Medicine for the Most Vulnerable At-Risk Patients
Restricted accessResearch articleFirst published online June, 2020
Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research: Personalized Infectious Disease Medicine for the Most Vulnerable At-Risk Patients
Mutation is the most powerful driver of change for life on Earth. Pathogenic bacteria utilize mutation as a means to survive strong live-die selective pressures generated by chemical antibiotics. As such, the traditional drug-making pipeline, characterized by significant financial and time investment, is insufficient to keep pace with the rapid evolution of bacterial resistance to structurally fixed and chemically unmalleable antibacterial compounds. In contrast, the genetic diversity and adaptive mutability of the bacteriophage can be leveraged to not only overcome resistance but also used for the development of enhanced traits that increase lytic potential and therapeutic efficacy in relevant host microenvironments. This is the fundamental premise behind Baylor College of Medicine's Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR) initiative. In this perspective, we outline the concept, structure, and process behind TAILΦR's attempt to generate a personalized therapeutic phage that addresses the most clinically challenging of bacterial infections.
Get full access to this article
View all access options for this article.
References
1.
DarwinC. On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life. London: John Murray;, 1859; 502.
2.
AbbottS, FairbanksDJ. Experiments on plant hybrids by Gregor Mendel. Genetics. 2016; 204:407–422.
3.
de VriesH, FarmerJB, DarbishireAD. The Mutation Theory; Experiments and Observations on the Origin of Species in the Vegetable Kingdom. Chicago, IL: Open Court Publishing Company. 1910. https://www.biodiversitylibrary.org/item/16402 (last accessed March20, 2020).
4.
GagerCS, de VriesH. IntracellularPangenesis. United States: Open Court Publishing Company;2014;270. ISBN: 9780875482095. Last accessed June11, 2020.
5.
HalesKG, KoreyCA, LarracuenteAM, et al.Genetics on the fly: A primer on the drosophila model system. Genetics. 2015; 201:815–842.
6.
WheelerDA, WangL. From human genome to cancer genome: The first decade. Genome Res. 2013; 23:1054–1062.
7.
ZhuYO, SiegalML, HallDW, et al.Precise estimates of mutation rate and spectrum in yeast. Proc Natl Acad Sci U S A. 2014; 111(22):E2310-8.
8.
MaressoAW. The mutagenic tetrasect. In: MaressoAW; ed. Bacterial Virulence: A Conceptual Primer. Cham: Springer International Publishing, 2019; pp. 5:9–71.
9.
MaressoAW.Antibiotics …and their destruction. In: Bacterial Virulence: A Conceptual Primer. MaressoAnthony W. (eds), Cham: Springer International Publishing, 2019, pp. 195–212.
10.
PierGB. On the greatly exaggerated reports of the death of infectious diseases. Clin Infect Dis. 2008; 47:1113–1114.
11.
Zaman SBin, HussainMA, NyeR, et al.A review on antibiotic resistance: Alarm bells are ringing. Cureus. 2017; 9:e1403.
12.
KolářM, UrbánekK, LátalT. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents. 2001; 17:357–363.
13.
ZhaoS, LiebermanTD, PoyetM, et al.Adaptive evolution within gut microbiomes of healthy people. Cell Host Microbe. 2019; 25:656.e8–667.e8.
14.
ColeGHA. Wandering stars: About planets and exo-planets: An introductory notebook. Singapore: World Scientific Publishing Company;2006:504. ISBN: 9781783260683.
15.
PalzkillT. Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC β-lactamases. Front Mol Biosci. 2018; 5:16.
16.
PatelMP, FryszczynBG, PalzkillT. Characterization of the global stabilizing substitution A77V and its role in the evolution of CTX-M β-Lactamases. Antimicrob Agents Chemother. 2015; 59:6741–6748.
17.
MunitaJM, AriasCA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016; 4:1–24.
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: CDC, 2019. www.cdc.gov/DrugResistance/Biggest-Threats.html Last accessed March20, 2020.
20.
Gordillo AltamiranoFL, BarrJJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019; 32:1–25.
21.
KortrightKE, ChanBK, KoffJL, et al.Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. Cell Host and Microbe. 2019; 25(2):219–232.
22.
SalmondGPC, FineranPC. A century of the phage: Past, present and future. Nat Rev Microbiol. 2015; 13(12):777–786.
23.
OfirG, SorekR. Contemporary phage biology: From classic models to new insights. Cell. 2018; 172:1260–1270.
24.
AbedonST, KuhlSJ, BlasdelBG, et al.Phage treatment of human infections. Bacteriophage. 2011; 1:66–85.
25.
HatfullGF, DedrickRM, Guerrero-BustamanteCA, et al.Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019; 25(5):730–733.
26.
Nir-PazR, GelmanD, KhouriA, et al.Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis. 2019; 69(11):2015–2018.
27.
SchooleyRT, BiswasB, GillJJ, et al.Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017; 61:e00954-17.
28.
DuplessisC, BiswasB, HanischB, et al.Refractory pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy. J Pediatric Infect Dis Soc. 2018; 7:253–256.
29.
AslamS, PretoriusV, LehmanSM, et al.Novel bacteriophage therapy for treatment of left ventricular assist device infection. J Hear Lung Transplant. 2019; 38:475–476.
30.
LavergneS, HamiltonT, BiswasB, et al.Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open Forum Infect Dis. 2018; 5(4):ofy064.
31.
AslamS, CourtwrightAM, KovalC, et al.Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant. 2019; 19:2631–2639.
32.
GibsonSB, GreenSI, LiuCG, et al.Constructing and characterizing bacteriophage libraries for phage therapy of human infections. Front Microbiol. 2019; 10:1–17.
33.
ClokieMRJ, KropinskiAM. Bacteriophages: Methods and protocols. Isolation, Characterization, and Interactions. Volume 1. United Kingdom: Humana Press; 2009:308. Last accessed June11, 2020.
34.
RajanA, VelaL, ZengXL, et al.Novel segment- and host-specific patterns of enteroaggregative Escherichia coli adherence to human intestinal enteroids. MBio. 2018; 9:1–15.
35.
GreenSI, KaelberJT, MaL, et al.Bacteriophages from ExPEC reservoirs kill pandemic multidrug-resistant strains of clonal group ST131 in animal models of bacteremia. Sci Rep. 2017; 7:1–13.
36.
MaL, GreenSI, TrautnerBW, et al.Metals enhance the killing of bacteria by bacteriophage in human blood. Sci Rep. 2018; 8:1–11.
37.
GreenSI, AjamiNJ, MaL, et al.Murine model of chemotherapy-induced extraintestinal pathogenic Escherichia coli translocation. Infect Immun. 2015; 83:3243–3256.
38.
ChatterjeeA, JohnsonCN, LuongP, et al.Bacteriophage resistance alters antibiotic-mediated intestinal expansion of enterococci. Infect Immun. 2019; 87(6):e00085-19.
39.
ChanBK, SistromM, WertzJE, et al.Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016; 6:1–8.
40.
ChenY, BatraH, DongJ, et al.Genetic engineering of bacteriophages against infectious diseases. Front Microbiol. 2019; 10:1–12.
41.
BrownR, LengelingA, WangB. Phage engineering: How advances in molecular biology and synthetic biology are being utilized to enhance the therapeutic potential of bacteriophages. Quant Biol. 2017; 5:42–54.
42.
PiresDP, CletoS, SillankorvaS, et al.Genetically engineered phages: A review of advances over the last. Microbiol Mol Biol Rev. 2016; 80:523–543.
43.
YehlK, YangAC, TorresMDT, et al.Engineering phage host-range and suppressing bacterial resistance through phage tail fiber article engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis. Cell. 2019; 179:459–469.
44.
AzeredoJ, SillankorvaS. Bacteriophage Therapy—From Lab to Clinical Practice. New York: Huaman Press, 2018.
45.
PhilipsonCW, VoegtlyLJ, LuederMR, et al.Characterizing phage genomes for therapeutic applications. Viruses. 2018; 10:188.
46.
MirzaeiMK, NilssonAS. Isolation of phages for phage therapy: A comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS One. 2015; 10(3):e0118557.
47.
Van BelleghemJD, DąbrowskaK, VaneechoutteM, et al.Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses. 2019; 11:10.
48.
El HaddadL, HarbCP, GebaraMA, et al.A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin Infect Dis. 2019; 69:167–178.
49.
GolecP, Dabrowski KamilK, HejnowiczMS, et al.A reliable method for storage of tailed phages. J Microbiol Methods. 2011; 84:486–489.
